Sun Pharma completes sale of two Ranbaxy divisions to Strides
Advertisement
New Delhi: Sun Pharma Industries said it has completed the process of selling two divisions of erstwhile Ranbaxy Laboratories to Strides Shasun for Rs 165 crore.
All the necessary formalities for closure of the said transaction have been completed and the aforesaid transaction has been successfully closed on February 1, 2016, Sun Pharma said in a regulatory filing.
Last month, the drug major had received an order from the Competition Commission of India (CCI) approving the proposed transaction for selling two divisions in the central nervous system (CNS) segment in India.
Last year, Sun Pharma and Strides Shasun (then Strides Arcolab) had inked a pact related to Ranbaxy's 'Solus' and 'Solus Care' divisions operating in the central nervous system (CNS) segment in India.
The agreement involved transfer of these two marketing divisions, along with employees to Strides, for Rs 165 crore.
Sun Pharma acquired Ranbaxy Laboratories in a $4 billion deal in 2014.
All the necessary formalities for closure of the said transaction have been completed and the aforesaid transaction has been successfully closed on February 1, 2016, Sun Pharma said in a regulatory filing.
Last month, the drug major had received an order from the Competition Commission of India (CCI) approving the proposed transaction for selling two divisions in the central nervous system (CNS) segment in India.
Last year, Sun Pharma and Strides Shasun (then Strides Arcolab) had inked a pact related to Ranbaxy's 'Solus' and 'Solus Care' divisions operating in the central nervous system (CNS) segment in India.
The agreement involved transfer of these two marketing divisions, along with employees to Strides, for Rs 165 crore.
Sun Pharma acquired Ranbaxy Laboratories in a $4 billion deal in 2014.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.